Meritage Group Nephros Inc transactions over time
NEPH
Nephros Inc historical holders
total: 1
Transactions details
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q3
Nathaniel Simons has been an institutional investor in Nephros Inc (NEPH) since 2026 Q3. According to 2026 Q3 report, Nathaniel Simons holds 173,407 shares with a market value of roughly $643.34K representing 0.02% of their equity portfolio. The fund/company first acquired NEPH in 2026 Q3, initially purchasing 173,407 shares.
Does Nathaniel Simons still hold NEPH?
Yes, Nathaniel Simons continues to hold Nephros Inc (NEPH). According to their 2026 Q3 report, they maintain a position of 173,407 shares valued at approximately $643.34K, representing 0.02% of their equity portfolio.
When did Nathaniel Simons first invest in NEPH?
Nathaniel Simons first invested in Nephros Inc (NEPH) in 2026 Q3 at the reported quarter-end price of $3.71 per share, acquiring 173,407 shares in their initial purchase.
What is Nathaniel Simons's average cost basis for NEPH?
Based on historical transaction data, Nathaniel Simons's estimated cost basis for Nephros Inc (NEPH) is approximately $3.71 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $3.71
NEPH transactions history by Meritage Group
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
0.02%
|
173,407
|
$3.71
|
$643,340
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.